Cargando…

Biomolecular Mechanisms of Cardiorenal Protection with Sodium-Glucose Co-Transporter 2 Inhibitors

Diabetes mellitus (DM) is a metabolic disorder characterized by chronic hyperglycemia and associated with an increased risk of morbidity and mortality, primarily from cardiovascular and renal diseases. Sodium-glucose cotransporter 2 inhibitors (SGLT2-Is) are novel drugs for the treatment of type 2 D...

Descripción completa

Detalles Bibliográficos
Autores principales:	Prandi, Francesca Romana, Barone, Lucy, Lecis, Dalgisio, Belli, Martina, Sergi, Domenico, Milite, Marialucia, Lerakis, Stamatios, Romeo, Francesco, Barillà, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599693/ https://www.ncbi.nlm.nih.gov/pubmed/36291558 http://dx.doi.org/10.3390/biom12101349

Ejemplares similares

Epigenetic Modifications and Non-Coding RNA in Diabetes-Mellitus-Induced Coronary Artery Disease: Pathophysiological Link and New Therapeutic Frontiers
por: Prandi, Francesca Romana, et al.
Publicado: (2022)

Treatment of HFpEF beyond the SGLT2-Is: Does the Addition of GLP-1 RA Improve Cardiometabolic Risk and Outcomes in Diabetic Patients?
por: Belli, Martina, et al.
Publicado: (2022)

Gut Microbiota Composition and Cardiovascular Disease: A Potential New Therapeutic Target?
por: Belli, Martina, et al.
Publicado: (2023)

Novel 3D Echocardiographic Technique for Mitral Calcium Mapping
por: Prandi, Francesca Romana, et al.
Publicado: (2023)

A Rare Case of Left Ventricular Non-Compaction with Coronary Artery Anomaly Complicated by ST-Elevation Myocardial Infarction and Subcutaneous Defibrillator Implantation
por: Prandi, Francesca Romana, et al.
Publicado: (2022)

Advances in Imaging for Tricuspid Transcatheter Edge-to-Edge Repair: Lessons Learned and Future Perspectives
por: Prandi, Francesca Romana, et al.
Publicado: (2023)

Glucose variability: a new risk factor for cardiovascular disease
por: Belli, Martina, et al.
Publicado: (2023)

Combined MitraClip and Left Atrial Appendage Occlusion: Is It Still a Utopia?
por: Belli, Martina, et al.
Publicado: (2022)

Protective Biomolecular Mechanisms of Glutathione Sodium Salt in Ischemia-Reperfusion Injury in Patients with Acute Coronary Syndrome-ST-Elevation Myocardial Infarction
por: Arrivi, Alessio, et al.
Publicado: (2022)

Coronary Obstruction during Valve-in-Valve Transcatheter Aortic Valve Replacement: Pre-Procedural Risk Evaluation, Intra-Procedural Monitoring, and Follow-Up
por: Prandi, Francesca Romana, et al.
Publicado: (2023)

Case report: Paravalvular regurgitation post transcatheter aortic valve replacement: When in doubt choose cardiac magnetic resonance
por: Hadley, Michael B., et al.
Publicado: (2022)

Concurrent cardiac and central nervous system complications of acute infective endocarditis: case report
por: Prandi, Francesca Romana, et al.
Publicado: (2022)

Inflammation in atherosclerotic cardiovascular disease
por: Shah, Prediman K., et al.
Publicado: (2019)

Downregulation of Circulating Hsa-miR-200c-3p Correlates with Dyslipidemia in Patients with Stable Coronary Artery Disease
por: Vancheri, Chiara, et al.
Publicado: (2023)

Cardiorenal protective effect of sodium–glucose cotransporter 2 inhibitors and mitochondrial function
por: Lee, Hong Kyu
Publicado: (2019)

Sodium-Glucose Cotransporter-2 Inhibition Benefits in Cardiorenal Risk in Men and Women
por: Pruett, Jacob E, et al.
Publicado: (2022)

Sodium–glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes
por: Giugliano, Dario, et al.
Publicado: (2021)

Prevention of Cardiorenal Complications with Sodium–Glucose Cotransporter Type 2 Inhibitors: A Narrative Review
por: Botana, Manuel, et al.
Publicado: (2022)

A Role of Sodium-Glucose Co-Transporter 2 in Cardiorenal Anemia Iron Deficiency Syndrome
por: Sano, Motoaki
Publicado: (2023)

Biomarkers in Cardiorenal Syndrome
por: Goffredo, Giovanni, et al.
Publicado: (2021)

Clinical Features and Management of COVID-19–Associated Hypercoagulability
por: Massaro, Gianluca, et al.
Publicado: (2022)

Sodium-Glucose Cotransporter 2 Inhibitors and Heart Failure: A Bedside-to-Bench Journey
por: Cappetta, Donato, et al.
Publicado: (2021)

The Deadly Quartet (Covid-19, Old Age, Lung Disease, and Heart Failure) Explains Why Coronavirus-Related Mortality in Northern Italy Was So High
por: Calcaterra, Giuseppe, et al.
Publicado: (2021)

Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering
por: Charytan, David M, et al.
Publicado: (2023)

Sodium Glucose Cotransporter Type 2 Inhibitors Improve Cardiorenal Outcome of Patients With Coronary Artery Disease: A Meta-Analysis
por: Wei, Wen, et al.
Publicado: (2022)

Non‐inferiority and clinical superiority of glucagon‐like peptide‐1 receptor agonists and sodium‐glucose co‐transporter‐2 inhibitors: Systematic analysis of cardiorenal outcome trials in type 2 diabetes
por: Zaccardi, Francesco, et al.
Publicado: (2022)

Cardiorenal syndrome and diabetes: an evil pairing
por: Méndez Fernández, Ana Belén, et al.
Publicado: (2023)

The Cardiorenal Syndrome
por: Rosner, Mitchell H., et al.
Publicado: (2011)

Cardiorenal syndrome
por: Schetz, Miet
Publicado: (2009)

Cardiorenal syndrome
por: Ye, Wen Qing Wendy, et al.
Publicado: (2023)

Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence
por: Schechter, Meir, et al.
Publicado: (2021)

Changing the diabetes treatment paradigm from glucose control to cardiorenal protection
por: Ekanayake, Preethika, et al.
Publicado: (2021)

The Effect of TAVR on Left Ventricular and Left Atrial Mechanics in Patients with Aortic Stenosis
por: Anastasius, Malcolm, et al.
Publicado: (2022)

Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose‐lowering agent: An analysis from VERTIS CV
por: Dagogo‐Jack, Samuel, et al.
Publicado: (2022)

Biomolecular phase separation through the lens of sodium‐23 NMR
por: Fuentes‐Monteverde, Juan Carlos, et al.
Publicado: (2020)

Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors: Delving Into the Potential Benefits of Cardiorenal Protection Beyond the Treatment of Type-2 Diabetes Mellitus
por: Srinivas, Natasha, et al.
Publicado: (2021)

A Systematic Review of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Sympathetic Nervous System Inhibition: An Underrated Mechanism of Cardiorenal Protection
por: Raza, Shafaat, et al.
Publicado: (2022)

Current Options and Future Perspectives in the Treatment of Dyslipidemia
por: Muscoli, Saverio, et al.
Publicado: (2022)

Cardiorenal Syndrome: New Pathways and Novel Biomarkers
por: Gembillo, Guido, et al.
Publicado: (2021)

The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection
por: Brown, Emily, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nlha4720t148gd8d4sl2trjpu8